[Changes in ultra rapid urease test and histopathological examination for Helicobacter pylori by antisecretory drugs].
BACKGROUND
One of the major problems when evaluating dyspeptic patients at public hospitals is the large interval between the consultation and the endoscopy, leading to the prescription of antisecretory drugs, what can be responsible for false results on examinations.


OBJECTIVE
To evaluate changes in ultrarapid urease test and histopathological examination for Helicobacter pylori by antisecretory drugs.


METHODS
In a prospective double-blind study, 50 patients with dyspeptic complaints and endoscopic diagnosis of peptic ulcer, erosive gastritis, esophagitis or duodenitis with a positive urease test, were randomized to a 7-day course of treatment with either omeprazole 20 mg or ranitidine 300 mg a day. Before and after treatment, two biopsy specimens each were obtained from the antrum and corpus and an ultrarapid urease test and a histopathological examination for Helicobacter pylori were performed.


RESULTS
There were no significant changes in the results of ultrarapid urease test and histopathological examination for Helicobacter pylori after treatment with ranitidine. With omeprazole, we observed a decrease in positive results in ultrarapid urease test and histopathological examination for Helicobacter pylori in the antrum, but not in the corpus.


CONCLUSIONS
Omeprazole, used for 7 days can lead to negative results in ultrarapid urease test and histopathological examination for Helicobacter pylori in the antrum, and should not be employed in patients before the endoscopy is performed.
Ferreira
L E
LE
Serviço de Gastroenterologia, Hospital Universitário, Universidade Federal de Juiz de Fora-UFJF, Juiz de Fora, MG.
Meirelles
G S
GS
Vieira
R R
RR
Bragagnolo Júnior
M A
MA
Chebli
J M
JM
de Souza
A F
AF
D000328:Adult; D000368:Aged; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D004796:Clinical Enzyme Tests / Q000379:methods*; D003951:Diagnostic Errors; D004311:Double-Blind Method; D005260:Female; D005753:Gastric Mucosa / Q000187:drug effects / Q000382:microbiology; D005767:Gastrointestinal Diseases / Q000175:diagnosis* / Q000188:drug therapy / Q000382:microbiology; D016481:Helicobacter Infections / Q000175:diagnosis* / Q000188:drug therapy / Q000382:microbiology; D016480:Helicobacter pylori / Q000187:drug effects / Q000302:isolation & purification*; D006635:Histamine H2 Antagonists / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000627:therapeutic use; D011446:Prospective Studies; D011899:Ranitidine / Q000627:therapeutic use; D014510:Urease / Q000032:analysis*
D000897:Anti-Ulcer Agents; D006635:Histamine H2 Antagonists; D011899:Ranitidine; D014510:Urease; D009853:Omeprazole